Препараты 1-й линии для купирования фибрилляции предсердий у пациентов с минимальными структурными изменениями сердца
Препараты 1-й линии для купирования фибрилляции предсердий у пациентов с минимальными структурными изменениями сердца
Миллер О.Н., Тарасов А.В., Павенко Е.Н. Препараты 1-й линии для купирования фибрилляции предсердий у пациентов с минимальными структурными изменениями сердца. Consilium Medicum. 2018; 20 (1): 66–70. DOI: 10.26442/2075-1753_2018.1.66-70
________________________________________________
Miller O.N., Tarasov A.V., Pavenko E.N. Preparations of the first line for atrial fibrillation of precurities in patients with minimal structural heart changes. Consilium Medicum. 2018; 20 (1): 66–70. DOI: 10.26442/2075-1753_2018.1.66-70
Препараты 1-й линии для купирования фибрилляции предсердий у пациентов с минимальными структурными изменениями сердца
Миллер О.Н., Тарасов А.В., Павенко Е.Н. Препараты 1-й линии для купирования фибрилляции предсердий у пациентов с минимальными структурными изменениями сердца. Consilium Medicum. 2018; 20 (1): 66–70. DOI: 10.26442/2075-1753_2018.1.66-70
________________________________________________
Miller O.N., Tarasov A.V., Pavenko E.N. Preparations of the first line for atrial fibrillation of precurities in patients with minimal structural heart changes. Consilium Medicum. 2018; 20 (1): 66–70. DOI: 10.26442/2075-1753_2018.1.66-70
Фибрилляция предсердий – наиболее частая аритмия, встречающаяся в клинической практике. С каждым годом число больных с фибрилляцией предсердий увеличивается, что в первую очередь связано с общим постарением населения, а также наличием сопутствующей патологии. С целью изучения данной проблемы, поисков оптимальной терапии и наиболее эффективного ведения пациентов проводится огромное количество исследований, которые, в свою очередь, служат основой для современных клинических рекомендаций. В данном обзоре приводятся современные способы медикаментозного восстановления синусового ритма. Мы попытались проанализировать обновленные рекомендации Европейского общества кардиологов 2016 г.
Ключевые слова: фибрилляция предсердий, восстановление синусового ритма.
________________________________________________
Atrial fibrillation is the most common arrhythmia in clinical practice. Number of patients with atrial fibrillation increases every year, primary due to the general aging of the population, as well as the presence of comorbidities. There are huge amount of research carried due to the search for optimal treatment and the most effective management of patients. In the given review the modern methods of the medicated sinus rhythm restoration and we analyzed updated recommendations of the Еuropean Society of Cardiology 2016 year.
Key words: atrial fibrillation, restoration of sinus rhythm.
1. 2016 ESC. Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. DOI: 10.1093/eurheartj/ehw210
2. Руксин В.В. Краткое руководство по неотложной кардиологии. СПб.: ИнформМед, 2010; с. 63. / Ruksin V.V. Kratkoe rukovodstvo po neotlozhnoi kardiologii. SPb.: InformMed, 2010; s. 63. [in Russian]
3. Sestito A, Molina E. Atrial fibrillation and the pharmacological treatment: the role of propafenone. Eur Rev Med Pharmacol Sci 2012; 16 (2): 242–53.
4. Boriani G, Biffi M, Capucci A et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized controlled trial. Ann Intern Med 1997; 126: 621–4.
5. Capucci A, Villiani G, Aschieri D. Safety of oral propafenone in the convertion of recept-onset atrial fibrillation to sinus rhythm: a prospective parallel placebo – controlled multicentred study. Int J Cardiol 1999; 68: 187–96.
6. Antonelli D, Darawsha A, Rimbrot S et al. Propafenone dose for emergency room conversion of paroxysmal atrial fibrillation. Harefuah 1999; 136 (11): 857–915.
7. Khan IA. Single oral loading dose of propafenone for pharmacological cardiover-sionofrecent-onsetatrial fibrillation. JACC 2001; 37: 542–7.
8. Alboni P, Botto GL, Baldi N et al. Outpatient treatment of recent-onset atrial fibrillation with the «pill-in-the-pocket» approach. N Engl J Med 2004; 351: 2384–91.
9. Deneer VH, Borgh MB, Kingma JH et al. Oral antiarrhythmic drugs in converting recent onset atrial fibrillation. Pharm World Sci 2004; 26 (2): 66–78.
10. Bunin YА, Anfalova L. Efficacy of propafenone as single oral loading dose in pharmacology converting recent-onset atrial fibrillation and atrial flutter. Europace 2005; 7 (Suppl. 1): 121–2.
11. Фомина И.Г., Таризманова А.И., Ветлужский А.В. и др. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. «ПРОМЕТЕЙ» – открытое, мультицентровое, пилотное исследование в Российской Федерации. Кардиоваск. терапия и профилактика. 2005; 4: 65–9. / Fomina I.G., Tarizmanova A.I., Vetluzhskii A.V. i dr. Propafenon pri vosstanovlenii sinusovogo ritma u bol'nykh s persistiruiushchei formoi fibrilliatsii predserdii. «PROMETEI» – otkrytoe, mul'titsentrovoe, pilotnoe issledovanie v Rossiiskoi Federatsii. Kardiovask. terapiia i profilaktika. 2005; 4: 65–9. [in Russian]
12. Zipes DP. Management of cardiac arrhytmias: Parmacological, electrical and surgical techniques. In: E.Braunwald (ed). Heart disease-5th edition. Philadelphia 1997: p. 593–639.
13. Feld GK. Atrial fibrillation. Is there a safe and highly effective pharmacological treatment? Circulation 1990; 82: 2248–50.
14. Leitch JW, Klein GJ, Yee R et al. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern. Circulation 1990; 82: 1718–23.
15. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000; 86: 950–3.
16. Chevalier P, Durand-Dubief A, Burri H et al. Amiodarone versus placebo and class IС drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003; 41 (2): 255–62.
17. Stoschitzky K, Stoschitzky G, Lercher P et al. Propafenone shows class Ic and class II antiarrhythmic effects. Europace 2016; 18 (4): 568–71.
18. Halpern SW, Ellroot G, Singh BN, Mandel WJ. Efficacy of intravenous procainamid infusion in converting atrial fibrillation to sinus rhythm. Relation to left atrium size. Brit Heart J 1980; 44: 589–95.
19. Fenster PE, Comess KA, Marsh A et al. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 1983; 106: 501–4.
20. Kochiadakis GE, Igoumenidis NE, Solomou MC et al. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther 1998; 12: 75–81.
21. Kochiadakis GE, Igoumenidis NE, Hamilos ME et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onsetatrial fibrillation. Am J Cardiol 2007; 99: 1721–25.
22. Stiell IG, Clement CM, Symington C et al. Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter. Acad Emerg Med 2007; 14: 1158–64.
23. Singh S, Saini RK, DiMarco J et al. Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group. Am J Cardiol 1991; 68: 1227–30.
24. Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 1990; 65: 679–80.
25. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebocontrolled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J 1997; 18: 649–54.
26. Barroffio R, Tisi G, Guzzini F et al. A randomised study comparing digoxin and propafenone in the treatment of recent onset atrial fibrillation. Clin Drug Invest 1995; 9: 277–83.
27. Hou ZY, Chang MS, Chen CY et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 1995; 16: 521–8.
________________________________________________
1. 2016 ESC. Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. DOI: 10.1093/eurheartj/ehw210
2. Ruksin V.V. Kratkoe rukovodstvo po neotlozhnoi kardiologii. SPb.: InformMed, 2010; s. 63. [in Russian]
3. Sestito A, Molina E. Atrial fibrillation and the pharmacological treatment: the role of propafenone. Eur Rev Med Pharmacol Sci 2012; 16 (2): 242–53.
4. Boriani G, Biffi M, Capucci A et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized controlled trial. Ann Intern Med 1997; 126: 621–4.
5. Capucci A, Villiani G, Aschieri D. Safety of oral propafenone in the convertion of recept-onset atrial fibrillation to sinus rhythm: a prospective parallel placebo – controlled multicentred study. Int J Cardiol 1999; 68: 187–96.
6. Antonelli D, Darawsha A, Rimbrot S et al. Propafenone dose for emergency room conversion of paroxysmal atrial fibrillation. Harefuah 1999; 136 (11): 857–915.
7. Khan IA. Single oral loading dose of propafenone for pharmacological cardiover-sionofrecent-onsetatrial fibrillation. JACC 2001; 37: 542–7.
8. Alboni P, Botto GL, Baldi N et al. Outpatient treatment of recent-onset atrial fibrillation with the «pill-in-the-pocket» approach. N Engl J Med 2004; 351: 2384–91.
9. Deneer VH, Borgh MB, Kingma JH et al. Oral antiarrhythmic drugs in converting recent onset atrial fibrillation. Pharm World Sci 2004; 26 (2): 66–78.
10. Bunin YА, Anfalova L. Efficacy of propafenone as single oral loading dose in pharmacology converting recent-onset atrial fibrillation and atrial flutter. Europace 2005; 7 (Suppl. 1): 121–2.
11. Fomina I.G., Tarizmanova A.I., Vetluzhskii A.V. i dr. Propafenon pri vosstanovlenii sinusovogo ritma u bol'nykh s persistiruiushchei formoi fibrilliatsii predserdii. «PROMETEI» – otkrytoe, mul'titsentrovoe, pilotnoe issledovanie v Rossiiskoi Federatsii. Kardiovask. terapiia i profilaktika. 2005; 4: 65–9. [in Russian]
12. Zipes DP. Management of cardiac arrhytmias: Parmacological, electrical and surgical techniques. In: E.Braunwald (ed). Heart disease-5th edition. Philadelphia 1997: p. 593–639.
13. Feld GK. Atrial fibrillation. Is there a safe and highly effective pharmacological treatment? Circulation 1990; 82: 2248–50.
14. Leitch JW, Klein GJ, Yee R et al. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern. Circulation 1990; 82: 1718–23.
15. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000; 86: 950–3.
16. Chevalier P, Durand-Dubief A, Burri H et al. Amiodarone versus placebo and class IС drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003; 41 (2): 255–62.
17. Stoschitzky K, Stoschitzky G, Lercher P et al. Propafenone shows class Ic and class II antiarrhythmic effects. Europace 2016; 18 (4): 568–71.
18. Halpern SW, Ellroot G, Singh BN, Mandel WJ. Efficacy of intravenous procainamid infusion in converting atrial fibrillation to sinus rhythm. Relation to left atrium size. Brit Heart J 1980; 44: 589–95.
19. Fenster PE, Comess KA, Marsh A et al. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J 1983; 106: 501–4.
20. Kochiadakis GE, Igoumenidis NE, Solomou MC et al. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther 1998; 12: 75–81.
21. Kochiadakis GE, Igoumenidis NE, Hamilos ME et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onsetatrial fibrillation. Am J Cardiol 2007; 99: 1721–25.
22. Stiell IG, Clement CM, Symington C et al. Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter. Acad Emerg Med 2007; 14: 1158–64.
23. Singh S, Saini RK, DiMarco J et al. Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The Sotalol Study Group. Am J Cardiol 1991; 68: 1227–30.
24. Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 1990; 65: 679–80.
25. Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebocontrolled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J 1997; 18: 649–54.
26. Barroffio R, Tisi G, Guzzini F et al. A randomised study comparing digoxin and propafenone in the treatment of recent onset atrial fibrillation. Clin Drug Invest 1995; 9: 277–83.
27. Hou ZY, Chang MS, Chen CY et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 1995; 16: 521–8.
Авторы
О.Н.Миллер*1, А.В.Тарасов2, Е.Н.Павенко3
1 ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России. 630091, Россия, Новосибирск, Красный пр-т, д. 52;
2 ФГБОУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России. 101990, Россия, Москва, Петроверигский пер., д. 10, стр. 3;
3 ФГБОУ ВО «Новосибирский государственный технический университет». 630073, Россия, Новосибирск, пр-т Карла Маркса, д. 20
1 Novosibirsk State Medical University of the Ministry of Health of the Russian Federation. 630091, Russian Federation, Novosibirsk, Krasnyi pr-t, d. 52;
2 National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation. 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3;
3 Novosibirsk State Technical University. 630073, Russian Federation, Novosibirsk, pr-t Karla Marksa, d. 20